Dornase alfa
From Wikipedia, the free encyclopedia
(Redirected from Pulmozyme)
Pharmaceutical drug
This article needs more reliable medical references for verification or relies too heavily on primary sources . Please review the contents of the article and add the appropriate references if you can. Unsourced or poorly sourced material may be challenged and removed. Find sources: "Dornase alfa" – news · newspapers · books · scholar · JSTOR (February 2022)
Pharmaceutical compound
| Clinical data | |
|---|---|
| Trade names | Pulmozyme |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a694002 |
| License data |
|
| Pregnancy category |
|
| Routes of administration | Inhalation |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number |
|
| DrugBank |
|
| ChemSpider |
|
| UNII | |
| KEGG | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.029.685 Edit this at Wikidata |
| Chemical and physical data | |
| Formula | C1321H1999N339O396S9 |
| Molar mass | 29254.04 g·mol−1 |
| ☒NcheckY (what is this?) (verify) | |
Dornase alfa, sold under the brand name Pulmozyme, is used for the treatment of cystic fibrosis.[3] It is a recombinant human deoxyribonuclease I (rhDNase), an enzyme which selectively cleaves DNA.[3] Dornase alfa hydrolyzes the DNA present in sputum/mucus and reduces viscosity in the lungs, promoting improved clearance of secretions.[3] It is produced in Chinese hamster ovary cells.[3]
Medical uses
[edit ]Dornase alfa is indicated for the management of people with cystic fibrosis to improve pulmonary function.[3]
Society and culture
[edit ]Legal status
[edit ]Dornase alfa is an orphan drug.[4]
Research
[edit ]Dornase alfa has been shown to improve lung function in non-cystic fibrosis pre-term infants atelectasis.[5] [6]
References
[edit ]- ^ a b Product guildlink.com.au
- ^ "Pulmozyme Product information". Health Canada . 25 April 2012. Retrieved 9 January 2023.
- ^ a b c d e f "Pulmozyme- dornase alfa solution". DailyMed. 21 October 2020. Retrieved 9 January 2023.
- ^ Collier, Joe (1 September 1995). "Dornase-alfa and orphan drugs". The Lancet. 346 (8975): 633. doi:10.1016/S0140-6736(95)91460-9. PMID 7651014. S2CID 5456247.
- ^ Erdeve O, Uras N, Atasay B, Arsan S (2007). "Efficacy and safety of nebulized recombinant human DNase as rescue treatment for persistent atelectasis in newborns: case-series". Croat Med J. 48 (2): 234–9. PMC 2080511 . PMID 17436388.
- ^ Hendriks T, de Hoog M, Lequin MH, Devos AS, Merkus PJ (2005). "DNase and atelectasis in non-cystic fibrosis pediatric patients". Crit Care. 9 (4): R351-6. doi:10.1186/cc3544 . PMC 1269442 . PMID 16137347.